Cargando…

Are We Ready for Proactive Therapeutic Drug Monitoring of Anti-TNF to Optimize Care of Patients With Inflammatory Bowel Disease?

Detalles Bibliográficos
Autor principal:	Charabaty, Aline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802329/ https://www.ncbi.nlm.nih.gov/pubmed/36777959 http://dx.doi.org/10.1093/crocol/otz056

Ejemplares similares

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

The Impact of Inflammatory Bowel Disease Related Content Shared on Twitter: Are We Reaching Other Health Care Professionals or Patients?
por: Charabaty, Aline
Publicado: (2021)

Are we ready for therapeutic drug monitoring of biologic therapeutics?
por: Krieckaert, Charlotte LM, et al.
Publicado: (2011)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges
por: Choden, Tenzin, et al.
Publicado: (2018)

Improving immunization strategies in patients with inflammatory bowel disease
por: Farshidpour, Maham, et al.
Publicado: (2019)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Are We Ready for Anything?
por: Neal-Boylan, Leslie
Publicado: (2020)

We are Ready for 2024!
Publicado: (2023)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Probiotics: Should We Use Them Proactively in Critical Illness?
por: Soni, Kapil Dev
Publicado: (2022)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Are we ready for submental diversions?
por: Kundra, Pankaj, et al.
Publicado: (2016)

The World is Changing – Are We Ready?
Publicado: (2016)

Are we ready for the new coronavirus?()
por: Peña-Otero, David, et al.
Publicado: (2020)

Personalised medicine: are we ready?
por: Louis, Renaud, et al.
Publicado: (2017)

Therapeutic drug monitoring in inflammatory bowel disease treatments
por: Wang, Meng-Yao, et al.
Publicado: (2022)

Updates in therapeutic drug monitoring in inflammatory bowel disease
por: Lodhia, Nilesh, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

When a COVID-19 vaccine is ready, will we all be ready for it?
por: Fadda, Marta, et al.
Publicado: (2020)

Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices
por: Bertani, Lorenzo
Publicado: (2022)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Atrial Fibrillation Ablation - Are we ready?
por: Deshpande, Shantanu, et al.
Publicado: (2007)

Infection and Chemotherapy: We Are Ready to Fly
por: Cheong, Hee Jin
Publicado: (2013)

One year on: Are we ready for COVID?()
por: Peña-Otero, David, et al.
Publicado: (2021)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
por: Cui, Guanglin, et al.
Publicado: (2021)

Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
por: Martins, Camilla de Almeida, et al.
Publicado: (2022)

Therapeutic drug monitoring for biological medications in inflammatory bowel disease
por: Cogan, Rachel C., et al.
Publicado: (2022)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers
por: Del Hoyo, Javier, et al.
Publicado: (2023)

Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease
por: Andersen, Vibeke, et al.
Publicado: (2017)

Ready for change: Oscillatory mechanisms of proactive motor control
por: Liebrand, Matthias, et al.
Publicado: (2018)

Are we ready to forget everything we have learned during the pandemic?
por: Hernández Ortiz, J.Á.
Publicado: (2022)

State of The Globe: Antimicrobial Resistance: Are we Ready?
por: Raina, Sunil Kumar
Publicado: (2019)

COVID-19 reinfection: are we ready for winter?
Publicado: (2020)

Neuroimaging at 7 T: are we ready for clinical transition?
por: Cosottini, Mirco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_omktk1ejtiqh0t5knhbsdme4vl